Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurobindo PharmaBOM:524804 +0.55%86 ROC (Joel Greenblatt) % is 22.86% as of Jun. 2026, which is 5% below its 10-year median of 24.11. GuruFocus rates BOM:524804 with a GF Score™ of 86/100 and a GF Value™ of ₹1,403.03 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 981 Drug Manufacturers companies, Aurobindo Pharma ranks better than 64.73% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Aurobindo Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 22.86%.
The historical rank and industry rank for Aurobindo Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:
BOM:524804'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.08 Med: 24.11 Max: 44.52
Current: 21.55
During the past 13 years, Aurobindo Pharma's highest ROC (Joel Greenblatt) % was 44.52%. The lowest was 14.08%. And the median was 24.11%.
BOM:524804's ROC (Joel Greenblatt) % is ranked better than 64.73% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.62
vs BOM:524804: 21.55
Aurobindo Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -8.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Aurobindo Pharma ROC (Joel Greenblatt) % Related Terms
Aurobindo Pharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Aurobindo Pharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524804 vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurobindo Pharma ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Aurobindo Pharma's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 22.86% mean?
Aurobindo Pharma (BOM:524804) has a ROC (Joel Greenblatt) % of 22.86% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Aurobindo Pharma and its competitors. This is near median its historical median of 24.11. Over the past decade, Aurobindo Pharma's ROC (Joel Greenblatt) % has ranged from 14.08 to 44.52. According to the industry distribution chart, Aurobindo Pharma ranks #346 out of 981 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Aurobindo Pharma's ROC (Joel Greenblatt) % too high?
Aurobindo Pharma's current ROC (Joel Greenblatt) % of 22.86% is near median its 10-year median of 24.11. Over the past 10 years, this metric has ranged from a low of 14.08 to a high of 44.52. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.62. Aurobindo Pharma's value of 22.86% is 96.7% above this industry median. Based on the distribution chart, Aurobindo Pharma ranks #346 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurobindo Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aurobindo Pharma ranks #346 out of 981 companies for ROC (Joel Greenblatt) %. This puts Aurobindo Pharma in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.62. Aurobindo Pharma's value of 22.86% is 96.7% above this benchmark. Historically, Aurobindo Pharma's own ROC (Joel Greenblatt) % has ranged from 14.08 to 44.52 over the past decade. While the company's 10-year median is 24.11 vs. the industry median of 11.62, Aurobindo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.62, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurobindo Pharma's current ROC (Joel Greenblatt) % of 22.86% is 96.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Aurobindo Pharma and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current ROC (Joel Greenblatt) % is 22.86%, which is near median its own 10-year median of 24.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,403.03, compared to a current price of ₹1,631.00 — trading 16.2% above its estimated fair value. The current ROC (Joel Greenblatt) % is 22.86%, which is near median its 10-year median of 24.11 and 96.7% above the Drug Manufacturers industry median of 11.62. Aurobindo Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current ROC (Joel Greenblatt) % is 22.86% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?
Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued.
The current stock price of ₹1,631.00 is trading 16.2% above its estimated GF Value™ of ₹1,403.03.
GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524804:
ROC (Joel Greenblatt) %: 22.86% (near median its 10-year median of 24.11)
GF Value™: ₹1,403.03 vs. price of ₹1,631.00 (16.2% above fair value)
Industry Position: 96.7% above the Drug Manufacturers median (#346 of 981)
No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
86GF Score
Get the complete analysis for BOM:524804
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524804 has been successfully added to your 
